首站-论文投稿智能助手
典型文献
Targeting apoptosis to manage acquired resistance to third generation EGFR inhibitors
文献摘要:
A significant clinical challenge in lung cancer treatment is management of the inevitable acquired resistance to third-generation epidermal growth factor receptor(EGFR)tyrosine kinase inhibitors(EGFR-TKIs),such as osimertinib,which have shown remarkable success in the treatment of advanced NSCLC with EGFR activating mutations,in order to achieve maximal response duration or treatment remission.Apoptosis is a major type of programmed cell death tightly associated with cancer development and treatment.Evasion of apoptosis is considered a key hallmark of cancer and acquisition of apoptosis resistance is accordingly a key mechanism of drug acquired resistance in cancer therapy.It has been clearly shown that effective induction of apoptosis is a key mechanism for third generation EGFR-TKIs,particularly osimertinib,to exert their therapeutic efficacies and the development of resistance to apoptosis is tightly associated with the emergence of acquired resistance.Hence,restoration of cell sensitivity to undergo apoptosis using various means promises an effective strategy for the management of acquired resistance to third generation EGFR-TKIs.
文献关键词:
作者姓名:
Shi-Yong Sun
作者机构:
Department of Hematology and Medical Oncology,Emory University School of Medicine and Winship Cancer Institute of Emory University,Atlanta,GA 30322,USA
文献出处:
引用格式:
[1]Shi-Yong Sun-.Targeting apoptosis to manage acquired resistance to third generation EGFR inhibitors)[J].医学前沿,2022(05):701-713
A类:
osimertinib
B类:
Targeting,apoptosis,acquired,resistance,third,generation,EGFR,inhibitors,significant,clinical,challenge,lung,cancer,treatment,management,inevitable,epidermal,growth,receptor,tyrosine,kinase,TKIs,such,which,have,shown,remarkable,success,advanced,NSCLC,activating,mutations,order,achieve,maximal,response,duration,remission,Apoptosis,major,type,programmed,cell,death,tightly,associated,development,Evasion,considered,key,hallmark,acquisition,accordingly,mechanism,drug,therapy,It,has,been,clearly,that,effective,induction,particularly,exert,their,therapeutic,efficacies,emergence,Hence,restoration,sensitivity,undergo,using,various,means,promises,strategy
AB值:
0.526642
相似文献
Clinical value of next-generation sequencing in guiding decisions regarding endocrine therapy for advanced HR-positive/HER-2-negative breast cancer
Dan Lyu;Binliang Liu;Bo Lan;Xiaoying Sun;Lixi Li;Jingtong Zhai;Haili Qian;Fei Ma-Department of Medical Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China;Department of Breast Cancer Medical Oncology,Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine,Central South University,Changsha 410013,China;Department of Medical Oncology,Cancer Hospital of Huanxing Chaoyang District,Beijing 100122,China;State Key Laboratory of Molecular Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China
Preclinical studies of the triazol0[1,5-a]pyrimidine derivative WS-716 as a highly potent,specific and orally active P-glycoprotein(P-gp)inhibitor
Sai-Qi Wang;Qiu-Xu Teng;Shuai Wang;Zi-Ning Lei;Hui-Hui Hu;Hui-Fang Lv;Bei-Bei Chen;Jian-Zheng Wang;Xiao-Jing Shi;Wei-Feng Xu;Hong-Min Liu;Xiao-Bing Chen;Zhe-Sheng Chen;Bin Yu-Department of Oncology,the Affiliated Cancer Hospital of Zhengzhou University,Henan Cancer Hospital,Henan Cancer Institute,Zhengzhou 450008,China;State Key Laboratory of Esophageal Cancer Prevention&Treatment,Zhengzhou University,Zhengzhou 450052,China;College of Pharmacy and Health Sciences,St.John,s University,Queens,NY 11439,USA;School of Pharmaceutical Sciences,Zhengzhou University,Zhengzhou 450001,China;Laboratory Animal Center,Academy of Medical Science,Zhengzhou University,Zhengzhou 450052,China
Acquisition of taxane resistance by p53 inactivation in ovarian cancer cells
Changfa Shu;Xi Zheng;Alafate Wuhafu;Danielle Cicka;Sean Doyle;Qiankun Niu;Dacheng Fan;Kun Qian;Andrey A.Ivanov;Yuhong Du;Xiulei Mo;Haian Fu-Department of Pharmacology and Chemical Biology,Emory University School of Medicine,Atlanta,GA 30322,USA;Department of Gynecology and Obstetrics,The Third Xiangya Hospital of Central South University,Changsha 410013,China;Cancer Institute,the Second Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou 310052,China;The First Affiliated Hospital,Medical School of Xi'an Jiaotong University,Xi'an 710061,China;Emory Chemical Biology Discovery Center,Emory University School of Medicine,Atlanta,GA 30322,USA;Department of Hematology and Medical Oncology and Winship Cancer Institute,Emory University,Atlanta,GA 30322,USA
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。